Serum brain-derived neurotrophic factor levels in epilepsy
1Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
European Journal of Neurology
|July 25, 2013
Summary
Serum brain-derived neurotrophic factor (BDNF) levels do not diagnose epilepsy but may indicate disease severity. Higher seizure frequency and epilepsy duration correlate with lower serum BDNF, suggesting its potential as a severity biomarker.
Area of Science:
- Neuroscience
- Biomarker Research
Background:
- Epilepsy diagnosis and severity assessment are critical clinical challenges.
- Brain-derived neurotrophic factor (BDNF) is implicated in neuronal function and plasticity.
Purpose of the Study:
- To evaluate serum BDNF as a diagnostic and severity biomarker for epilepsy.
- To investigate the correlation between serum BDNF levels and epilepsy characteristics.
Main Methods:
- Serum BDNF levels were measured in 135 individuals with epilepsy and 34 healthy controls using Luminex technology.
- Statistical analyses, including multiple linear regression, were employed to assess correlations.
Main Results:
- Serum BDNF levels did not differ between individuals with epilepsy and controls.
- Seizure frequency and epilepsy duration showed a negative correlation with serum BDNF levels.
- A BDNF cut-off value demonstrated 80% sensitivity and 90% specificity for distinguishing frequent seizures.
Conclusions:
- Serum BDNF concentration is associated with epilepsy severity.
- Serum BDNF may serve as a valuable biomarker for assessing epilepsy disease severity.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
00:49The Blood-brain Barrier
Overview
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...